Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients

Inclusion Criteria: * Patient's written informed consent obtained prior to any study-related procedures. * Outpatient male or female aged ≥ 18 years. * Evidence for "partly controlled" asthma in the 2 weeks before the screening visit * Under previous inhaled corticosteroids (ICS) treatment at the screening visit * Forced expiratory volume in the first second (FEV1) ≥ 60% and ≤ 90% of the predicted normal values at the screening visit. * A documented positive response to the reversibility test at the screening visit, defined as ΔFEV1 ≥ 12% and ≥ 200 mL over baseline, 30 minutes after 400 μg salbutamol pMDI * Patients free of long-acting beta2-agonists (LABAs) treatment for at least 2 weeks before the screening visit. * Patients free of short-acting beta2-agonists (SABAs) treatment for at least 6 hours before the screening visit. * Non-smokers or ex-smokers Exclusion Criteria: * Pregnant or lactating women or all women physiologically capable of becoming pregnant UNLESS they are menopausal or are using effective and acceptable methods of contraception. * Significant seasonal variation in asthma or asthma occurring only during episodic exposure to an allergen or a chemical sensitizer. * History of near fatal asthma (e.g. brittle asthma, hospitalisation for asthma exacerbation in Intensive Care Unit) within 1 year before screening. * Occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks preceding the screening visit. * Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) * History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency. * Diagnosis of restrictive lung disease. * Patients treated with oral or parenteral corticosteroids in the previous 8 weeks (12 weeks for parenteral depot corticosteroids) before screening visit. * Intolerance or contra-indication to treatment with beta2-agonists and/or inhaled corticosteroids. * Allergy, sensitivity or intolerance to study drugs or excipients. * Significant medical history of and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, or any laboratory abnormality.